Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly

American Journal of Cardiovascular Drugs · Published 2025-11-17 · DOI 10.1007/s40256-025-00777-2

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40256-025-00777-2

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Colchicine for Cardiovascular Prevention: Clarity Amidst the Confusion · American Journal of Cardiovascular Drugs · 2025 · Same journal
Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy · American Journal of Cardiovascular Drugs · 2025 · Same journal
Cardiovascular Outcomes Associated with Cholinesterase Inhibitor Use in Individuals at High Cardiovascular Risk · American Journal of Cardiovascular Drugs · 2025 · Same journal
Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies · American Journal of Cardiovascular Drugs · 2025 · Same journal
One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry · American Journal of Cardiovascular Drugs · 2025 · Same journal
De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making · American Journal of Cardiovascular Drugs · 2026 · Same journal
Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy · American Journal of Cardiovascular Drugs · 2025 · Same journal
Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study · American Journal of Cardiovascular Drugs · 2026 · Same journal
Disproportionality Analysis of Ivabradine in the US FDA Adverse Event Reporting System: A Real-World Study Across Overall and Indication-Specific Populations · American Journal of Cardiovascular Drugs · 2025 · Same journal
Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction · American Journal of Cardiovascular Drugs · 2025 · Same journal